The quarterly is cashflow and includes the receipts from December, 2007 where ther were virtually no sales.
Read further about Bioscreens and they are launching the new product in Texas as we speak.
They can also use FDA approval from Visuline for this product.
" SBL has obtained independent advice that the BioScreens Cup will be adequately covered by its existing FDA approvals provided the product is propriately labeled."
Cash flow deficeit per month reduced from $80,000 predicted to around $50,000 per month.
Mr Sun would prefer to have shares at 65 years of age rather than money
AVITAR has settled thereby protecting our PATENT.
New distributors in US, as per my posts, have only come on in APRIL 2008
New distributors in Latin America.
Distributors in Russia and Poland progressing on time.
Oraline 8 -
"Customers will continue to have available the current four drugs and can select one of the two combinations of four drugs. This flexibility allows SBL to offer combinations that are in demand in the US yet also address the different requirements found in China and Europe. Discussions with existing distributors indicate that the ability to test for 8 drugs rather than 4 will provide SBL with a significant advantage over its competitors"
China- Full steam ahead.
And I will leave you with this thought.
Quote: "Management currently estimates that sales from the development of Oraline 8, the BioScreens and China projects (discussed further below) will begin to make a significant impact upon the business in the early 2009"
And that's from a conservative management.
•
SBN Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
